Spotlight on cefditoren pivoxil in bacterial infections

Treatments in Respiratory Medicine

Volumn 4, Issue 2, 2005, Pages 149-152

  Wellington, Keri ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; BETA LACTAMASE; CARNITINE; CEFDITOREN PIVOXIL; CEFOTAXIME; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MAGNESIUM DERIVATIVE; METICILLIN; PENICILLIN G; PENICILLIN V;

ABDOMINAL PAIN; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; HYDROLYSIS; MAXILLA SINUSITIS; MORAXELLA CATARRHALIS; NAUSEA; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TONSILLITIS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HUMANS; MAXILLARY SINUSITIS; TONSILLITIS;

EID: 18144431034     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200504020-00012     Document Type: Article

References (42)

1. Dubois J, St-Pierre C. Superior inhibitory and bactericidal activity of celditoren against respiratory tract pathogens [poster no. 370]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
2. Peric M, Browne FA, Jacobs MR, et al. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin Ther 2003 Jan; 25 (1): 169-77
3. Seki H, Kasahara Y, Ohta K, et al. Antimicrobial activities of cefditoren against respiratory pathogens isolated from children in Japan. J Infect Chemother 1999 Mar; 5 (1): 16-20
4. Sahm DF, Draghi D, Blosser RS, et al. Comparative activities of cefditoren and other antimicrobials against recent clinical isolates of non-pneumococcal streptococci collected throughout the United States [poster no. 375]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
5. Granizo JJ, Fernandez-Roblas R, Coronel P, et al. In vitro susceptibility of 590 isolates of S. pyogenes against cefditoren and 10 other antimicrobials: a multicenter international study in Southern Europe (ARISE Project) [abstract no. P1368]. Clin Microbiol Infect 2002 Apr; 8 Suppl. 1: 320
6. Jones RN, Biedenbach DJ, Croco MAT, et al. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31: 573-8
7. Kelly LM, Jacobs MR, Appelbaum PC. Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae. J Clin Microbiol 1999; 37 (10): 3296-9
8. Fuchs PC, Barry AL, Brown SD. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria. Diagn Microbiol Infect Dis 2000; 37: 265-9
9. Ednie LM, Pankuch GA, Jacobs MR, et al. Activity of cefditoren compared with other agents against quinolone and macrolide susceptible and resistant pneumococci [poster no. 378]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
10. Beyer J, Shortridge V, Flamm R, et al. In vitro activity of cefditoren against clinical isolates of S. pneumoniae, H. influenzae, and M. Catarrhalis [poster no. 376]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
11. Clark CL, Nagai K, Dewasse BE, et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002 Jul; 50 (1): 33-41
12. Karlowsky JA, Jones ME, Draghi DC, et al. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis 2002 Jan; 42 (1): 59-64
13. Soriano F, Granizo JJ, Fenoll A, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J Chemother 2003 Apr; 15 (2): 107-12
14. Johnson DM, Biedenbach DJ, Beach ML, et al. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37 (2): 99-105
15. Sahm DF, Karlowsky JA, Draghi D, et al. Comparative activities of cefditoren and other antimicrobials against recent clinical isolates of H. influenzae and M. catarrhalis collected throughout the United States [poster no. 369]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
16. Karlowsky JA, Critchley IA, Draghi DC, et al. Activity of cefditoren against β-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 2002 Jan; 42 (1): 53-8
17. Soriano F, Granizo JJ, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries: the ARISE project. Int J Antimicrob Agents 2004 Mar; 23 (3): 296-9
18. Nishi J, Yoshinaga M, Tokuda K, et al. Oral antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates from Japanese children. Int J Antimicrob Agents 2002; 20: 130-5
19. Ehrhardt AF, Moland ES, Sanders CC. Impact of specific β-lactamase and β-lactamase/porin combinations on the in vitro activity of cefditoren in a genetically defined panel [poster no. 374]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
20. Medeiros AA. Comparison of oral cephalosporins and their activity against β-lactamase-producing bacteria. Infect Dis Clin Pract 1998 Nov; 7 Suppl. 4: S273-9
21. Jones RN, Pfaller MA, Jacobs MR, et al. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis 2001; 41 (1-2): 1-14
22. Guay DR. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 2001 Dec; 23 (12): 1924-37
23. Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren [poster no. 310]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
24. Mulford D, Mayer M, Witt G. Effect of renal impairment on the pharmacokinetics of cefditoren [poster no. 311]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
25. Mayer M, Mulford D, Witt G. Effect of hepatic impairment on the pharmacokinetics of cefditoren [poster no. 312]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
26. 2 receptor antagonist or an antacid on the pharmacokinetics of cefditoren [poster no. 313]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
27. Purdue Pharmaceutical Products L.P. Package insert: Spectracef® tablets (cefditoren pivoxil) [online]. Available from URL: http://www.pharma.com/PI/Prescription/spectracef.pdf (Accessed 2004 Aug 23]
28. Kinzig-Schippers M, Hinder M, Göhler K, et al. Tissue penetration of cefditoren (CEE) into bronchial mucosa (BM) and epithelial lining fluid (ELF) in patients undergoing fiberoptic bronchoscopy [abstract no. 946]. 41st Interscience Conference on Antimicrobials Agents and Chemotherapy; 2001 Dec 16-19; Chicago, 24
29. Mayer M, Mulford D, Witt G. Pharmacokinetics of cefditoren in blister fluid and plasma [abstract no. 656]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 20
30. Tedec-Meiji Farma S.A. Summary of product characteristics: Spectracef® film-coated tablets. Madrid: Tedec-Meiji Farina S.A., 2004
31. Henry DC, Poling TL, Bettis RB, et al. A double-blind, randomized study of cefditoren vs cefuroxime for AECB. J Respir Dis 2001; 22 (8 Suppl.): S69-74
32. Tucker R, Rhudy J, Hunt B, et al. Safety and efficacy of cefditoren in acute exacerbation of chronic bronchitis (AECB) [abstract no. 836 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 495
33. Tedec-Meiji Farma S.A. Efficacy of cefditoren-pivoxil compared to cefuroximeaxetil in patients with acute exacerbation of chronic bronchitis in adults. Tedec-Meiji Farina S.A., 2001 (Data on file)
34. Fogarty CM, Cyganowski M, Palo WA, et al. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002 Nov; 24 (11): 1854-70
35. van Zyl L, le Roux JO, LaFata JA, et al. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clin Ther 2002 Nov; 24 (11): 1840-53
36. Comparative safety and efficacy of cefditoren pivoxil and Augmentin® (amoxicillin/clavulanate potassium) in the treatment of patients with acute maxillary sinusitis. TAP Holdings Inc., 1999 (Data on file)
37. Multicentre, prospective, comparative, phase III study of cefditoren-pivoxil (CDTR-PI) versus cefuroxime-axetil in the treatment of acute community-acquired sinusitis (ACAS) in adults. Tedec-Meiji Farma S.A., 2001 (Data on file)
38. Gooch W, Marsh D, Stickler T, et al. Cefditoren is safe and effective treatment for streptococcal pharyngitis [abstract no. 837 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 495
39. Multicentre phase III, randomised, comparative study: cefditoren pivoxil (ME1207) with penicillin V in the treatment of acute bacterial pharyngotonsillitis in adults. Tedec-Meiji Farma S.A., 2001 (Data on file)
40. Bucko AD, Hunt BJ, Kidd SL, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400mg bid with either cefuroxime 250mg bid or cefadroxil 500 mg bid for the treatment of uncomplicated skin and skin-structure infections. Clin Ther 2002; 24 (7): 1134-47
41. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002; 54 (4): 589-98
42. Brass EP, Mayer MD, Mulford DJ, et al. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clin Pharmacol Ther 2003 Apr; 73 (4): 338-47